目的 分析郑州市第二人民医院降眼压药物的临床使用情况及用药趋势。方法 收集郑州市第二人民医院2022—2025年降眼压药品出库记录，以销售金额、消耗量为分析指标，通过销售金额/消耗量（B/A）值评价金额与用量的同步性。结果 2022—2025年郑州市第二人民医院降眼压药品销售总额增长86.97%。前列腺素类衍生物B/A值最高，复方制剂增速最快，α受体激动剂用量增长显著，β受体抑制剂B/A值最低。结论 郑州市第二人民医院降眼压药品使用呈现基础药物β受体抑制剂与一线药物前列腺素类衍生物并重，联合治疗日益重视的特点，表明临床选药需在疗效优先的前提下，兼顾患者经济承受能力与用药依从性，实现个体化治疗。

Objective To analyze the clinical utilization and medication trends of intraocular pressure-lowering drugs in Zhengzhou Second People’s Hospital. Methods The dispensing records of intraocular pressure-lowering drugs were collected in Zhengzhou Second People’s Hospital from 2022 to 2025. Using sales amount and consumption volume as indicators, the B/A value was employed to evaluate the synchronization between sales amount and consumption volume. Results From 2022 to 2025, the total sales amount of intraocular pressure-lowering drugs in our hospital increased by 86.97%. Prostaglandin analogs accounted for the highest B/A value, compound preparations exhibited the fastest growth rate, the consumption volume of α receptor agonists increased significantly, and β receptor blockers presented the characteristics with the lowest B/A value. Conclusion The utilization of intraocular pressure-lowering drugs in Zhengzhou Second People’s Hospital is characterized by an equal emphasis on essential drugs β receptor blockers and first-line drugs prostaglandin analogs, as well as an increasing focus on combination therapy. This indicates that clinical drug selection should prioritize efficacy while taking into account patients' economic affordability and medication compliance, so as to achieve individualized treatment.

R988.1

郑州市医学科研项目（ZZYK2024019）